The accompanying notes are an integral part of
these unaudited condensed financial statements.
The accompanying notes are an integral part of
these unaudited condensed financial statements.
The accompanying notes are an integral part of
these unaudited condensed financial statements.
The accompanying notes are an integral part of
these unaudited condensed financial statements.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Note 1 — Organization and Business Operation
Arisz Acquisition Corp. (“Arisz” or
the “Company”) is a newly organized blank check company incorporated as a Delaware corporation on July 21, 2021. The Company
was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business
combination with one or more businesses or entities (“Business Combination”). The Company has selected September 30 as its
fiscal year end.
As of December 31, 2022, the Company had not commenced
any operations. All activities through December 31, 2022 are related to the Company’s formation and the Initial Public Offering
(“IPO” as defined below in Note 3) and, subsequent to the IPO, identifying a target company for a Business Combination. The
Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will
generate non-operating income in the form of interest income from the proceeds derived from the IPO.
The Company’s sponsor is Arisz Investments
LLC (the “Sponsor”), a Delaware limited liability company affiliated with the Company’s Chairman and Chief Executive
Officer.
On January 21, 2022, Arisz entered into a merger
agreement with Finfront Holding Company, a Cayman Islands exempted company (the “BitFuFu”), pursuant to which (a) Arisz agreed
to form BitFuFu Inc., a Cayman Islands exempted company, as its wholly owned subsidiary (“Purchaser” or “PubCo”),
(b) Purchaser would form Boundary Holding Company, a Cayman Islands exempted company, as its wholly owned subsidiary (“Merger Sub”),
(c) Arisz will be merged with and into Purchaser (the “Redomestication Merger”), with Purchaser surviving the Redomestication
Merger, and (d) Merger Sub will be merged with and into BitFuFu (the “Acquisition Merger”), with the Company surviving the
Acquisition Merger as a direct, wholly owned subsidiary of Purchaser (collectively, the “Business Combination”). Following
the Business Combination, Purchaser will be a publicly traded company listed on a stock exchange in the United States. On April 4,
2022, each of Arisz and BitFuFu entered into that certain Amendment to the Merger Agreement pursuant to which, among other things, the
parties clarified certain Cayman Island corporate law matters by mutual agreement.
On July 14, 2022, each of Arisz, BitFuFu, the
Purchaser and Arisz’s Sponsor (along with any assignee of Arisz’s Sponsor, the “Buyer”) entered into a backstop
agreement (the “Backstop Agreement”) whereby, in connection with the Business Combination, the Buyer has agreed to subscribe
for and purchase no less than US$1.25 million worth of shares of Arisz common stock par value $0.0001 per share or Purchaser’s Class
A ordinary shares.
On October 10, 2022, Arisz and BitFuFu entered
into an amendment to the Merger Agreement to provide, among other things: 1) for a loan from BitFuFu to Arisz in the amount of $2,220,000
(the “Loan”) for the purpose of funding Arisz’s extension of the time to consummate a business combination and for working
capital purposes, and 2) remove all existing restrictions on 400,000 Insider Shares that are currently subject to transfer restrictions,
so that such shares are freely tradeable upon the Closing. The Loan will be funded in three equal installments of $740,000 on each of
October 26, 2022, January 26, 2023 and April 26, 2023, and 3) extend the Outside Date to August 1, 2023.
On October 10, 2022, Arisz issued an unsecured promissory
note to BitFuFu for the amount of the Loan at an interest rate of 3.5% per annum and is due on October 26, 2023. Arisz may elect to issue
a number of unregistered shares of its common stock, valued for these purposes at $10.00 per share, the aggregate value of which shall
be equal to the outstanding principal amount of the Loan to the BitFuFu or its designee on or prior to the October 26, 2023 in lieu of
paying all outstanding principal under this Note.
On October 13, 2022, the parties to the Backstop
Agreement entered into a new backstop agreement substantially on the same terms as the Backstop Agreement with the only substantive additional
terms being that: 1) the subscription amount is $2.0 million worth of shares and 2) the termination date is the earlier of: (i) the date
agreed by the parties thereto in writing and (ii) the date that the Merger Agreement is terminated, on its terms.
On October 24, 2022, Arisz received $740,000, the
first installment of the Loan, from BitFuFu.
On November 9, 2022, Arisz deposited $690,000 into
the Trust Account (representing $0.10 per each share of redeemable common stock) to extend the time for Arisz to complete the Business
Combination by three months until February 22, 2023.
On January 20, 2023, Arisz received $740,000,
the second installment of the Loan, from BitFuFu.
On February 7, 2023, the Company notified
the trustee of its intent to extend the time available to the Company to consummate a business combination from February 22, 2023 to
May 22, 2023 (the “Extension”). The Extension is the second of up to two three-month extensions permitted under
Arisz’s governing documents.
On February 9, 2023, Arisz deposited $690,000 into the Trust Account
(representing $0.10 per each share of redeemable common stock) to extend the time for Arisz to complete the Business Combination by three
months until May 22, 2023.
Financing
The registration statement for the Company’s
IPO became effective on November 17, 2021. On November 22, 2021 the Company consummated the IPO of 6,000,000 units (which does not include
the exercise of the over-allotment option by the underwriters in the IPO) at an offering price of $10.00 per unit (the “Public Units’),
generating gross proceeds of $60,000,000. Simultaneously with the IPO, the Company sold to its Sponsor and Chardan Capital Markets LLC
(“Chardan”) (and/or their designees) 253,889 units at $10.00 per unit (the “Private Units”) in a private placement
generating total gross proceeds of $2,538,886, which is described in Note 4.
Concurrently, the Company repaid $105,000 to the
Sponsor, under related party loan evidenced by promissory note issued on August 5, 2021.
The Company granted the underwriters a 45-day
option to purchase up to 900,000 additional Units to cover over-allotments, if any. On November 24, 2021, the underwriters fully exercised
the over-allotment option and purchased 900,000 units (the “Over-allotment Units”) at a price of $10.00 per Unit, generating
gross proceeds of $9,000,000. Upon the closing of the Over-allotment on November 24, 2021, the Company consummated the sale of additional
22,500 Private Units (the “Additional Private Units”) with the Sponsor and Chardan at a price of $10.00 per Private Unit,
generating total proceeds of $225,000.
Transaction costs amounted to $5,587,733, consisting
of $1,725,000 of underwriting fees, $2,587,500 of deferred underwriting fees (payable only upon completion of a Business Combination)
and $1,275,233 of other offering costs.
Trust Account
Upon closing of the IPO, the Private Units,
the sale of the Over-allotment Units and the sale of the Additional Private Units, a total of $69,000,000 ($10.00 per Unit) was
placed in a U.S.-based trust account (the “Trust Account”) with Continental Stock Transfer & Trust acting as trustee
and can be invested only in U.S. government treasury bills with a maturity of 180 days or less or in money market funds meeting
certain conditions under Rule 2a-7 under the Investment Company Act and that invest only in direct U.S. government treasury
obligations. These funds will not be released until the earlier of the completion of the initial Business Combination and the
liquidation due to the Company’s failure to complete a Business Combination within the applicable period of time. The proceeds
deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have
priority over the claims of the Company’s public stockholders. In addition, interest income earned on the funds in the Trust
account may be released to the Company to pay its income or other tax obligations. With these exceptions, expenses incurred by the
Company may be paid prior to a business combination only from the net proceeds of the IPO and private placement not held in the
Trust Account.
Business Combination
Pursuant to NASDAQ listing rules, the Company’s
initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80%
of the value of the funds in the Trust account (excluding any taxes payable on the income earned on the Trust account), which the Company
refers to as the 80% test, at the time of the execution of a definitive agreement for its initial business combination, although the Company
may structure a business combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust
account balance. If the Company is no longer listed on NASDAQ, it will not be required to satisfy the 80% test.
The Public Shares subject to redemption will be
recorded at a redemption value and classified as temporary equity upon the completion of the IPO in accordance with the Accounting Standards
Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed
with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination
and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder
vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company
will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”),
conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file
tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is
required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem
shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally,
each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction.
If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor and any of the Company’s
officers or directors that may hold Insider Shares (as defined in Note 5) (the “Initial Stockholders”) and Chardan have agreed
(a) to vote their Insider Shares, Private Shares (as defined in Note 4) and any Public Shares purchased during or after the IPO in favor
of approving a Business Combination and (b) not to convert any shares (including the Insider Shares) in connection with a stockholder
vote to approve, or sell the shares to the Company in any tender offer in connection with, a proposed Business Combination.
The Company will provide its holders of the outstanding
Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the
completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or
(ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct
a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public
Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro
rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income
tax obligations). If the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to
the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate
of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under
Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its
shares with respect to more than an aggregate of 20% or more of the Public Shares, without the prior consent of the Company.
The Initial Stockholders and Chardan have agreed
(a) to waive their redemption rights with respect to the Insider Shares, Private Shares, Underwriter Shares and Public Shares held by
them in connection with the completion of a Business Combination and (b) not to propose, or vote in favor of, an amendment to the Amended
and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of
its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders with the
opportunity to redeem their Public Shares in conjunction with any such amendment.
The Company will have until 15 months (or up to
18 months if the time to complete a business combination is extended as described herein) from the closing of the IPO to consummate a
Business Combination. In addition, if the Company anticipates that it may not be able to consummate initial business combination within
15 months, the Company’s insiders or their affiliates may, but are not obligated to, extend the period of time to consummate a business
combination two times by an additional three months each time (for a total of 18 months to complete a business combination) (the “Combination
Period”).
Liquidation
If the Company is unable to complete a
Business Combination within the Combination Period, unless the Company seeks and obtains stockholder approval to amend its Amended
and Restated Certificate of Incorporation to extend the date by which an initial business combination may be consummated, the
Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more
than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount
then on deposit in the Trust Account including interest (which interest shall be net of taxes payable, and less certain amount of
interest to pay dissolution expenses) divided by the number of then outstanding Public Shares, which redemption will completely
extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if
any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of
the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case
to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable
law.
The Sponsor and Chardan have agreed to waive their
liquidation rights with respect to the Insider Shares and Private Shares if the Company fails to complete a Business Combination within
the Combination Period. However, if the Sponsor or underwriters acquires Public Shares in or after the IPO, such Public Shares will be
entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination
Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account
in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will
be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the
event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than
$10.00.
In order to protect the amounts held in the Trust
Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products
sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce
the amount of funds in the Trust Account to below $10.00 per Public Share, except as to any claims by a third party who executed a valid
and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held
in the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of IPO against certain liabilities,
including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an
executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability
for such third party claims.
Going Concern Consideration
As of December 31, 2022, cash of $165,606 and a working
capital deficit of $790,056 (excluding income tax and franchise tax payable). The Company has 15 months (or up to 18 months if the time
to complete a business combination is extended as described herein) from the closing of the IPO to consummate a Business Combination.
It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by
this date, there will be a mandatory liquidation and subsequent dissolution.
The Company expects to continue to incur significant
professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of
a Business Combination. The Company may need to obtain additional financing either to complete its Business Combination or because it
becomes obligated to redeem a significant number of public shares upon consummation of its Business Combination, in which case the Company
may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities
laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is
unable to complete its Business Combination because it does not have sufficient funds available, it will be forced to cease operations
and liquidate the Trust Account.
On November 9, 2022, the Company deposited
$690,000 into the Trust Account (representing $0.10 per each share of redeemable common stock) to extend the time for Arisz to
complete the Business Combination by three months until February 22, 2023. On February 7, 2023, the Company notified the trustee of
its intent to extend the time available to the Company to consummate a business combination from February 22, 2023 to May 22, 2023
(the “Extension”). The Extension is the second of up to two three-month extensions permitted under Arisz’s
governing documents. On February 9, 2023, Arisz deposited $690,000 into the Trust Account (representing $0.10 per each share of
redeemable common stock) to extend the time for Arisz to complete the Business Combination by three months until May 22, 2023. It is
uncertain that the Company will be able consummate a Business Combination by the extended date (May 22, 2023). If a Business
Combination is not consummated by the required date, unless the Company seeks stockholder approval to amend its Amended and Restated Certificate of Incorporation to extend the date by which
an initial business combination may be consummated, there will be a mandatory liquidation and subsequent dissolution. In
connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard
Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s
Ability to Continue as a Going Concern,” management has determined that if the Company is unable to complete a Business
Combination within 18 months from the closing of the IPO, then the Company will cease all operations except for the purpose of
liquidating. The date for liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to
continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be
required to liquidate.
Risks and Uncertainties
Management is currently evaluating the impact
of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect
on the Company’s future financial position, results of its operations and/or search for a target company, there has not been a significant
impact as of the date of these financial statements. The financial statements do not include any adjustments that might result from the
future outcome of this uncertainty.
Additionally, as a result of the military action
commenced in February 2022 by the Russian Federation and Belarus in the country of Ukraine and related economic sanctions, the Company’s
ability to consummate a Business Combination, or the operations of a target business with which the Company ultimately consummates a Business
Combination, may be materially and adversely affected. In addition, the Company’s ability to consummate a transaction may be dependent
on the ability to raise equity and debt financing which may be impacted by these events, including as a result of increased market volatility,
or decreased market liquidity in third-party financing being unavailable on terms acceptable to the Company or at all. The impact of this
action and related sanctions on the world economy and the specific impact on the Company’s financial position, results of operations
and/or ability to consummate a Business Combination are not yet determinable. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
Inflation Reduction Act of 2022
On August 16, 2022, the Inflation Reduction Act
of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise
tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic
subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders
from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at
the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair
market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition,
certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority
to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The IR Act applies only to
repurchases that occur after December 31, 2022.
Any redemption or other repurchase that occurs
after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether
and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise
would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business
Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE”
or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination
but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury.
In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment
of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business
Combination and in the Company’s ability to complete a Business Combination.
At this time, it has been determined that none
of the IR Act tax provisions have an impact to the Company’s fiscal 2022 tax provision. The Company will continue to monitor for
updates to the Company’s business along with guidance issued with respect to the IR Act to determine whether any adjustments are
needed to the Company’s tax provision in future periods.
Note 2 — Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial
statements are presented in U.S. Dollars and in conformity with accounting principles generally accepted in the United States of America
(“GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and
footnotes required by GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation
have been included. Operating results for the three months ended December 31, 2022 are not necessarily indicative of the results that
may be expected for the year ending September 30, 2023 or any future period.
Emerging Growth Company Status
The Company is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart
Our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means
that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.
Use of Estimates
In preparing these financial statements in conformity
with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting
period.
Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near
term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. The Company had $165,606 in cash and did not
have any cash equivalents as of December 31, 2022.
Investments held in Trust Account
At December 31, 2022, the assets held in the Trust
Account were held in money market funds, which are invested in U.S. Treasury securities.
The Company classifies its U.S. Treasury and equivalent
securities as held-to-maturity in accordance with ASC Topic 320 “Investments — Debt and Equity Securities.” Held-to-maturity
securities are those securities which the Company has the ability and intent to hold until maturity. Held-to- maturity treasury securities
are recorded at amortized cost on the accompanying balance sheet and adjusted for the amortization or accretion of premiums or discounts.
Offering Costs
The Company complies with the requirements of
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A – “Expenses of Offering”. Offering costs $5,587,733 consisting
primarily of underwriting, legal, accounting, registration and other expenses incurred through the balance sheet date that are directly
related to the IPO and charged to shareholders’ equity upon the completion of the IPO.
Warrants
The Company accounts for warrants as either equity-classified
or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance
in Financial Accounting Standards Board (“FASB”) ASC 480 “Distinguishing Liabilities from Equity” (“ASC
480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding
financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants
meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s
own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside
of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance.
For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded
as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair
value of the warrants are recognized as a non-cash gain or loss on the statements of operations.
Common Stock Subject to Possible Redemption
The Company accounts for its common stock subject
to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Common stock
subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable
common stock (including common stock that feature redemption rights that is either within the control of the holder or subject to redemption
upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other
times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that
are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, as of December
31, 2022, shares of common stock subject to possible redemption are presented at redemption value of $10.21 per share as temporary
equity, outside of the shareholders’ equity section of the Company’s balance sheet. The Company recognizes changes in redemption
value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end
of each reporting period. Increases or decreases in the carrying amount of shares of redeemable common stock are affected by charges
against additional paid in capital or accumulated deficit if additional paid in capital equals to zero.
Concentration of Credit Risk
Financial instruments that potentially subject
the Company to concentration of credit risk consist of a cash account in a financial institution and money market funds held in the
Trust Account. The Company has not experienced losses on this account and management believes the Company is not exposed to significant
risks on such account.
Fair Value of Financial Instruments
The fair value of the Company’s assets and
liabilities, which qualify as financial instruments under ASC 825, “Financial Instruments,” approximates the carrying amounts
represented in the accompanying balance sheet, primarily due to their short-term nature.
Net Income (Loss) per Share
The Company complies with accounting and disclosure
requirements of FASB ASC 260, Earnings Per Share. The statements of operations include a presentation of income (loss) per redeemable
share and income (loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income
(loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss)
allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net
loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number
of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the
common shares subject to possible redemption was considered to be dividends paid to the public shareholders. As of December 31, 2022,
the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary
shares and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the
period presented.
The net income (loss) per share presented in the
statements of operations is based on the following:
| |
For the three months ended December 31, 2022 | | |
For the three months ended
December 31, 2021 | |
Net income (loss) | |
$ | 187,375 | | |
$ | (95,390 | ) |
Accretion of common stock to redemption value | |
| (1,176,246 | ) | |
| (14,145,764 | ) |
Net loss including accretion of common stock to redemption value | |
$ | (988,871 | ) | |
$ | (14,241,154 | ) |
| |
For the three months ended
December 31, 2022 | |
| |
Redeemable shares | | |
Non- redeemable shares | |
Basic and diluted net income/(loss) per share: | |
| | |
| |
Numerators: | |
| | |
| |
Allocation of net loss including accretion of common stock | |
$ | (766,533 | ) | |
$ | (222,338 | ) |
Accretion of common stock to redemption value | |
| 1,176,246 | | |
| — | |
Allocation of net income (loss) | |
$ | 409,713 | | |
$ | (222,338 | ) |
| |
| | | |
| | |
Denominators: | |
| | | |
| | |
Weighted-average shares outstanding | |
| 6,900,000 | | |
| 2,001,389 | |
Basic and diluted net income/(loss) per share | |
$ | 0.06 | | |
$ | (0.11 | ) |
| |
For the three months ended December 31,
2021 | |
| |
Redeemable shares | | |
Non- redeemable shares | |
Basic and diluted net income/(loss) per share: | |
| | |
| |
Numerators: | |
| | |
| |
Allocation of net loss including accretion of common stock | |
$ | (8,716,196 | ) | |
$ | (5,524,958 | ) |
Accretion of common stock to redemption value | |
| 14,145,764 | | |
| — | |
Allocation of net income (loss) | |
$ | 5,429,568 | | |
$ | (5,524,958 | ) |
| |
| | | |
| | |
Denominators: | |
| | | |
| | |
Weighted-average shares outstanding | |
| 2,905,435 | | |
| 1,841,676 | |
Basic and diluted net income/(loss) per share | |
$ | 1.87 | | |
$ | (3.00 | ) |
Income Taxes
The Company accounts for income taxes under ASC
740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected
impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit
to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when
it is more likely than not that all or a portion of deferred tax assets will not be realized.
The Company’s effective tax rate was 34.63%
and 0.00% for the three months ended December 31, 2022 and 2021, respectively. The effective tax rate differs from the statutory tax rate
of 21% for the three months ended December 31, 2022 and 2021, due to non-deductible M&A costs.
ASC 740 also clarifies the accounting for uncertainty
in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process
for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits
to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides
guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
While ASC 740 identifies usage of an effective
annual tax rate for purposes of an interim provision, it does allow for estimating individual elements in the current period if they are
significant, unusual or infrequent. Computing the effective tax rate for the Company is complicated due to the potential impact of the
timing of any Business Combination expenses and the actual interest income that will be recognized during the year. The Company has taken
a position as to the calculation of income tax expense in a current period based on ASC 740-270-25-3 which states, “If an entity
is unable to estimate a part of its ordinary income (or loss) or the related tax (benefit) but is otherwise able to make a reasonable
estimate, the tax (or benefit) applicable to the item that cannot be estimated shall be reported in the interim period in which the item
is reported.” The Company believes its calculation to be a reliable estimate and allows it to properly take into account the usual
elements that can impact its annualized book income and its impact on the effective tax rate. As such, the Company is computing its taxable
income (loss) and associated income tax provision based on actual results through December 31, 2022.
The Company recognizes accrued interest and penalties
related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest
and penalties as of December 31, 2022. The Company is currently not aware of any issues under review that could result in significant
payments, accruals or material deviation from its position.
The Company has identified the United States and
the State of New York as its only “major” tax jurisdictions.
The Company may be subject to potential examination
by federal and state taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing
and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s
management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Recent Accounting Standards
In August 2020, the Financial Accounting Standards
Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”)
to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial
conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining
to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible
debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings
per share guidance, including the requirement to use the if-converted method for all convertible instruments. The amendments are effective
for smaller reporting companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years.
The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or
cash flows.
Management does not believe that any recently
issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.
Note 3 — Initial Public Offering
Pursuant to the IPO on November 22, 2021, the
Company sold 6,000,000 Units at $10.00 per Public Unit, generating gross proceeds of $60,000,000. The Company granted the underwriters
a 45-day option to purchase up to 900,000 additional Units to cover over-allotments, if any. On November 24, 2021, the underwriters fully
exercised the over-allotment option and purchased 900,000 units at a price of $10.00 per Unit, generating gross proceeds of $9,000,000.
Each Public Unit consists of one share of common stock (“Public Share”), one right (“Public Right”) and one redeemable
warrant (“Public Warrant”). Each Public Right will convert into one-twentieth (1/20) of one share of common stock upon the
consummation of a Business Combination. Each whole Public Warrant entitles the holder to purchase three-fourths (3/4) of one share of
common stock at a price of $11.50 per whole share, subject to adjustment. The warrants will become exercisable on the later of 30 days
after the completion of the Company’s initial Business Combination or 15 months from the closing of the IPO, and will expire five
years after the completion of the Company’s initial Business Combination or earlier upon redemption or liquidation.
All of the 6,900,000 Public Shares sold
as part of the Public Units in the IPO contain a redemption feature which allows for the redemption of such Public Shares if there is
a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s
amended and restated certificate of incorporation, or in connection with the Company’s liquidation. In accordance with the SEC and
its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely
within the control of the Company require common stock subject to redemption to be classified outside of permanent equity.
The Company’s redeemable common stock is
subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable
that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the
period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the
earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying
amount of the instrument to equal the redemption value at the end of each reporting period. The Company has elected to recognize the changes
immediately. The accretion or remeasurement is treated as a deemed dividend (i.e., a reduction to retained earnings, or in absence of
retained earnings, additional paid-in capital).
As of December 31, 2022, the shares of common
stock reflected on the balance sheets are reconciled in the following table.
| |
As of December 31, 2022 | |
Gross proceeds | |
$ | 69,000,000 | |
Less: | |
| | |
Proceeds allocated to Public Warrants | |
| (6,658,289 | ) |
Proceeds allocated to Public Rights | |
| (2,726,727 | ) |
Offering costs of Public Shares | |
| (4,760,749 | ) |
Plus: | |
| | |
Additional amount deposited into trust | |
| 690,000 | |
Accretion of carrying value to redemption value | |
| 14,918,810 | |
Class A Common stock subject to possible redemption | |
$ | 70,463,045 | |
Note 4 — Private Placement
Simultaneously with the closing of the IPO, the
Sponsor and Chardan (and/or their designees) purchased an aggregate of 253,889 Private Units at a price of $10.00 per Private Unit for
an aggregate purchase price of $2,538,886 in a private placement. Upon the closing of the Over-allotment on November 24, 2021, the Company
consummated the sale of additional 22,500 Private Units with the Sponsor and Chardan at a price of $10.00 per Private Unit, generating
total proceeds of $225,000. The Private Units are identical to the Public Units except with respect to certain registration rights and
transfer restrictions. The proceeds from the Private Units were added to the proceeds from the IPO to be held in the Trust Account. If
the Company does not complete a Business Combination within the Combination Period, unless the Company seeks and obtains stockholder approval to amend its Amended and Restated Certificate of Incorporation to extend the
date by which an initial business combination may be consummated, the proceeds from the sale of the Private Units will
be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Units and all underlying
securities will expire worthless.
Note 5 — Related Party Transactions
Insider Shares
On August 5, 2021, the Company issued 1,437,500
shares of common stock to the Initial Stockholders (the “Insider Shares”) for an aggregated consideration of $25,000. On October
29, 2021, the Company effected a 1.2-for-1.0 stock split of common stock, resulting in the Sponsor holding an aggregate of 1,725,000 Insider
Shares, for approximately $0.014 per share, of which, up to 225,000 shares subject to forfeiture by the Initial Stockholders to the extent
that the underwriters’ over-allotment is not exercised in full, so that the Initial Stockholders will collectively own 20% of the
Company’s issued and outstanding shares after the IPO. As the over-allotment option was fully exercised on November 24, 2021, no
portion of the Insider Shares are subject to forfeiture.
The Initial Stockholders have agreed, subject
to certain limited exceptions, not to transfer, assign or sell any of their Insider Shares until, with respect to 50% of the Insider Shares,
the earlier of six months after the consummation of a Business Combination and the date on which the closing price of the common
stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like)
for any 20 trading days within a 30-trading day period commencing after a Business Combination and, with respect to the remaining
50% of the Insider Shares, until the six months after the consummation of a Business Combination, or earlier, in either case, if,
subsequent to a Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results
in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property.
Promissory Note — Related Party
On August 5, 2021, the Sponsor agreed to
loan the Company up to an aggregate amount of $300,000 to be used, in part, for transaction costs incurred in connection with the IPO
(the “Promissory Note”). The Promissory Note is unsecured, interest-free and due on the earlier of March 31, 2022 or
the closing the IPO. Concurrently with the IPO, the Company repaid the outstanding balance of $105,000 to the Sponsor.
Administrative Services Agreement
The Company entered into an administrative services
agreement with the Sponsor pursuant to which the Company pays a total of $10,000 per month for office space, administrative and support
services. Upon completion of the initial Business Combination or liquidation, the Company will cease paying these monthly fees. However,
pursuant to the terms of such agreement, the Sponsor agreed to defer the payment of such monthly fee. Any such unpaid amount will accrue
without interest and be due and payable no later than the date of the consummation of the initial Business Combination. For the three
months ended December 31, 2022 and December 31, 2021, the Company incurred $30,000 and $10,000, respectively, in fees for these services,
of which $30,000 and $10,000 are included in accounts payable and accrued expenses in the balance sheets December 31, 2022 and December
31, 2021, respectively.
Note 6 — Commitments and
Contingencies Risks and Uncertainties
Management is currently evaluating the impact
of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect
on the Company’s future financial position, results of its operations and/or search for a target company, there has not been a significant
impact as of the date of these financial statements. The financial statements do not include any adjustments that might result from the
future outcome of this uncertainty.
Registration Rights
The holders of the insider shares, the private
units, securities underlying the Unit Purchase Option and any units that may be issued upon conversion of working capital loans or extension
loans (and any securities underlying the private units or units issued upon conversion of the working capital loans or extension loans)
will be entitled to registration rights pursuant to a registration rights agreement signed prior to or on the effective date of IPO requiring
the Company to register such securities for resale. The holders of these securities are entitled to make up to two demands, excluding
short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration
rights with respect to registration statements filed subsequent to the completion of the initial business combination. The Company will
bear the expenses incurred in connection with the filing of any such registration statements.
Right of First Refusal
The Company has granted Chardan for a period of
24 months after the date of the consummation of the Company’s Business Combination, a right of first refusal to act as book-running
manager, with at least 30% of the economics, for any and all future public and private equity and debt offerings.
Underwriting Agreement
The Company has granted Chardan, the representative
of the underwriters, a 45-day option from the date of the IPO to purchase up to 900,000 additional Units to cover over-allotments,
if any, at the IPO price less the underwriting discounts and commissions.
The underwriters were paid a cash underwriting
discount of 2.5% of the gross proceeds of the IPO (including the exercise of the over-allotment option), or $1,725,000. In addition, the
underwriters will be entitled to a deferred fee of 3.75% of the gross proceeds of the IPO (including the exercise of the over-allotment
option), or $2,587,500, which will be paid upon the closing of a Business Combination from the amounts held in the Trust Account, subject
to the terms of the underwriting agreement. The underwriters will also be entitled to 0.75% of the gross proceeds of the IPO in the form
of common stock of the Company at a price of $10.00 per share, to be issued if the Company closes a Business Combination.
Unit Purchase Option
The Company sold to Chardan (and/or its designees),
for $100, an option (the “Unit Purchase Option”) to purchase 115,000 units (as the over-allotment option was fully exercised
on November 24, 2021) exercisable at $11.50 per Unit (or an aggregate exercise price of $1,322,500) commencing on the later of six months
from the effective date of the registration statement related to the IPO and the consummation of a Business Combination. The Unit Purchase
Option may be exercised for cash or on a cashless basis, at the holder’s option, and expires five years from the effective date
of the registration statement related to the IPO. The Units issuable upon exercise of the Unit Purchase Option are identical to those
offered in the IPO. The Company accounts for the Unit Purchase Option, inclusive of the receipt of $100 cash payment, as an expense of
the IPO resulting in a charge directly to stockholders’ equity. The option and the underlying securities that may be issued upon
exercise of the option, have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)
of FINRA’s NASDAQ Conduct Rules. Additionally, the option may not be sold, transferred, assigned, pledged or hypothecated for a
one-year period (including the foregoing 180-day period) following the date of IPO except to any underwriter and selected dealer participating
in the IPO and their bona fide officers or partners. The Unit Purchase Option grants to holders demand and “piggy back” rights
for periods of five and seven years, respectively, from the effective date of the registration statement with respect to the registration
under the Securities Act of the securities directly and indirectly issuable upon exercise of the Unit Purchase Option. The Company will
bear all fees and expenses attendant to registering the securities, other than underwriting commissions which will be paid for by the
holders themselves. The exercise price and number of units issuable upon exercise of the Unit Purchase Option.
Note 7 — Stockholders’ Equity
Common Stock — The
Company is authorized to issue 15,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the common stock are
entitled to one vote for each share. On October 29, 2021, the Company effected a 1.2-for-1.0 stock split of common stock, resulting in
the Sponsor holding an aggregate of 1,725,000 Insider Shares, for approximately $0.014 per share. At December 31, 2022, there were 2,001,389
shares of common stock issued and outstanding (excluding 6,900,000 shares subject to possible redemption).
Rights — Each holder
of a right will receive one-twentieth (1/20) of one share of common stock upon consummation of a Business Combination, even if the holder
of such right redeemed all shares held by it in connection with a Business Combination. No fractional shares will be issued upon conversion
of the rights. No additional consideration will be required to be paid by a holder of rights in order to receive its additional shares
upon consummation of a Business Combination, as the consideration related thereto has been included in the Unit purchase price paid for
by investors in the Initial Public Offering. If the Company enters into a definitive agreement for a Business Combination in which the
Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share
consideration the holders of the common stock will receive in the transaction on an as-converted into common stock basis and each holder
of a right will be required to affirmatively covert its rights in order to receive 1/20 share underlying each right (without paying additional
consideration). The shares issuable upon conversion of the rights will be freely tradable (except to the extent held by affiliates of
the Company).
If the Company is unable to complete a Business
Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive
any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of
the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure
to deliver securities to the holders of the rights upon consummation of a Business Combination. Additionally, in no event will the Company
be required to net cash settle the rights. Accordingly, holders of the rights might not receive the shares of common stock underlying
the rights.
Warrants — Each redeemable warrant entitles
the holder thereof to purchase three-fourths (3/4) of one share of common stock at a price of $11.50 per full share and will become exercisable
on the later of the completion of an initial Business Combination and 12 months from the closing of the IPO. However, no public warrants
will be exercisable for cash unless the foregoing, if a registration statement covering the issuance of the common stock issuable upon
exercise of the public warrants is not effective within 90 days from the closing of the Company’s initial Business Combination,
warrant holders may, until such time as there is an effective registration statement and during any period when we shall have failed to
maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration
under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a
cashless basis. The warrants will expire five years from the closing of the Company’s initial Business Combination at 5:00 p.m.,
New York City time or earlier redemption.
In addition, if (x) the Company issues additional
shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of the Company’s
initial Business Combination at an issue price or effective issue price of less than $9.50 per share (with such issue price or effective
issue price to be determined in good faith by our board of directors), (y) the aggregate gross proceeds from such issuances represent
more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination,
and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting
on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market
Price”) is below $9.50 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115%
of the Market Price, and the $16.50 per share redemption trigger price described below will be adjusted (to the nearest cent) to be equal
to 165% of the Market Value.
The Company may redeem the outstanding warrants:
| ● | in whole and not in part; |
|
● |
at a price of $0.01 per warrant; |
|
● |
upon a minimum of 30 days’ prior written notice of redemption, which the Company refers to as the 30-day redemption period; |
|
● |
if, and only if, the last reported sale price of the Company’s common stock equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the to the warrant holders. |
If the Company calls the Public Warrants for redemption,
management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,”
as described in the warrant agreement. In such event, each holder would pay the exercise price by surrendering the whole warrants for
that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common
stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value”
(defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price
of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption
is sent to the holders of warrants.
Except as described above, no warrants will be
exercisable and the Company will not be obligated to issue common stock unless at the time a holder seeks to exercise such warrant, a
prospectus relating to the common stock issuable upon exercise of the warrants is current and the common stock have been registered or
qualified or deemed to be exempt under the securities laws of the state of residence of the holder of the warrants. Under the terms of
the warrant agreement, the Company has agreed to use its best efforts to meet these conditions and to maintain a current prospectus relating
to the common stock issuable upon exercise of the warrants until the expiration of the warrants. However, the Company cannot assure that
it will be able to do so and, if the Company does not maintain a current prospectus relating to the common stock issuable upon exercise
of the warrants, holders will be unable to exercise their warrants and the Company will not be required to settle any such warrant exercise.
If the prospectus relating to the common stock issuable upon the exercise of the warrants is not current or if the common stock is not
qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, the Company will not be required
to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and
the warrants may expire worthless.
The private warrants have terms and provisions
that are identical to those of the warrants being sold as part of the units in the IPO except that the private warrants will be entitled
to registration rights. The private warrants (including the common stock issuable upon exercise of the private warrants) will not be transferable,
assignable or salable until 30 days after the completion of our initial business combination except to permitted transferees.
Note 8 — Fair Value Measurements
The fair value of the Company’s financial
assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale
of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the
measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of
observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions
about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities
based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1: |
|
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. |
|
|
|
Level 2: |
|
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. |
|
|
|
Level 3: |
|
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
The following table presents information about
the Company’s assets that are measured at fair value on a recurring basis at December 31, 2022 and indicates the fair value hierarchy
of the valuation inputs the Company utilized to determine such fair value.
| |
December 31, 2022 | | |
Quoted Prices in Active Markets (Level 1) | | |
Significant Other Observable Inputs (Level 2) | | |
Significant Other Unobservable Inputs (Level 3) | |
Assets | |
| | |
| | |
| | |
| |
Trust Account - U.S. Treasury Securities Money Market Fund | |
$ | 70,463,045 | | |
$ | 70,463,045 | | |
| — | | |
| — | |
Note 9 - Promissory Note to BitFuFu
Pursuant to the Merger Agreement, on October 10, 2022,
the Company issued an unsecured promissory note to BitFuFu up to an aggregate amount of $2,220,000 (see Note 1) at an interest rate of
3.5% per annum and is due on October 26, 2023. Arisz may elect to issue a number of unregistered shares of its common stock, valued for
these purposes at $10.00 per share, the aggregate value of which shall be equal to the outstanding principal amount of the Loan to the
BitFuFu or its designee on or prior to the October 26, 2023 in lieu of paying all outstanding principal under this Note. As of December
31, 2022, $740,000 of the Note was outstanding with an accrued interest of approximately $4,825.
Note 10 — Subsequent Events
The Company evaluated subsequent events and transactions
that occurred after the balance sheet date through February 13, 2022 when the financial statements were issued. Based on the review as
further disclosed in the footnotes and except as disclosed below, the Company did not identify any other subsequent events that would
have required adjustment or disclosure in the financial statements.
On January 20, 2023, Arisz received $740,000,
the second installment of the Loan, from BitFuFu.
On February 7, 2023, the Company notified the
trustee of its intent to extend the time available to the Company to consummate a business combination from February 22, 2023 to May
22, 2023 (the “Extension”). The Extension is the second of up to two three-month extensions permitted under
Arisz’s governing documents. On February 9, 2023, Arisz deposited $690,000 into the Trust Account (representing $0.10 per each
share of redeemable common stock) to extend the time for Arisz to complete the Business Combination by three months until May 22,
2023.